相关实验视频

Updated: May 13, 2026

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet

Published on: July 31, 2021

特米纳利亚卡塔帕 (Terminalia catappa) 水性提取物降低了糖尿病-高胆固醇贫血小鼠的高血糖和氧化应激

Ojaskumar D Agrawal¹, Yogesh A Kulkarni²

¹Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, V.L. Mehta Road, Vile Parle (W), Mumbai, 400 056, India; Vivekanand Education Society's College of Pharmacy, Chembur (E), University of Mumbai, Mumbai 400 074, India.

Journal of Ayurveda and integrative medicine

|January 19, 2025

概括

在2型糖尿病大鼠中,Terminalia catappa叶子提取物显著降低了血糖和改善了脂质概况. 这种药用植物提取物表现出显著的抗糖尿病作用,提供了潜在的治疗益处.

科学领域:

药理学药理学是指药理学的学科.
糖尿病学糖尿病学
植物医学植物医学

背景情况:

卡塔帕 (Terminalia catappa) 是一个公认的药用植物.
特米纳利亚属表现出已知的抗糖尿病特性.

研究的目的:

为了研究Terminalia catappa叶的抗糖尿病作用,提取了叶子中的水性提取物.
评估提取物对2型糖尿病大鼠生物化学和氧化应激标志物的影响.

主要方法:

在使用高脂肪饮食和 estreptozotocin 的老鼠中诱导了 2 型糖尿病.
鼠被用500和1000毫克/公斤的Terminalia catappa水性提取物治疗了六周.
评估了生物化学参数,氧化应激标志物和胰腺组织病理学.

主要成果:

提取物显著降低了糖尿病大鼠的葡萄糖,胆固醇和甘油三水平.
胰岛素敏感度指数 (ISI) 增强,而HOMA-IR和胰岛素水平下降.
GSH和触酶水平增加,通过增加SIRT1表达,可以预防胰腺损伤.

结论:

特米纳利亚卡塔帕 (Terminalia catappa) 水性提取物显示出显著的抗糖尿病活性.
提取物有效地减轻高血糖症,并改善2型糖尿病的代谢参数.
这些发现支持Terminalia catappa的使用,因为它具有抗糖尿病的潜力.

关键词:

有高脂肪的饮食.过高血糖症的发生.胰岛素耐药性胰岛素耐药性是一种色素 (tannin) 是一种色素.终端卡塔帕卡塔帕卡塔帕卡塔帕卡塔帕卡塔帕 2 型糖尿病 2 型糖尿病

更多相关视频

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

相关概念视频

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...